Once-weekly semaglutide use in glucagon-like peptide-1 receptor agonist na ïve patients with type 2 diabetes in North Macedonia: Real-world data from the MIRAGE study

The MIRAGE study aimed to evaluate the real-world use of once weekly (OW) subcutaneous semaglutide in glucagon-like peptide-1 receptor agonist na ïve type 2 diabetes patients in routine clinical practice in North Macedonia.
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Source Type: research